Search Within

Alexander Edward Drilon

Formats
  1. Meeting Abstract (374)
  2. Journal Article (223)
  3. Review (23)
  4. Editorial (6)
  5. Correspondence (3)
  6. Book Section (2)
  7. Research Letter (2)
  8. Book Whole (1)
  9. Guidelines (1)
  10. Miscellaneous (1)
Groups
  1. Department of Medicine (636)
  2. Solid Tumor Oncology Division (636)
  3. Thoracic Oncology (636)
  4. Department of Pathology and Laboratory Medicine (208)
  5. GSK Faculty (189)
  6. Human Oncology and Pathogenesis Program (158)

More Groups

People
  1. Marc Ladanyi (122)
  2. Mark Kris (90)
  3. Maria Arcila (82)
  4. David Hyman (78)
  5. Bob Li (65)
  6. Charles Rudin (64)

More People

Years
  1. 2025 (20)
  2. 2024 (61)
  3. 2023 (68)
  4. 2022 (85)
  5. 2021 (76)
  6. 2020 (81)

More Years

Publications
  1. Journal of Clinical Oncology (138)
  2. Annals of Oncology (94)
  3. Journal of Thoracic Oncology (84)
  4. Clinical Cancer Research (31)
  5. JCO Precision Oncology (24)
  6. Cancer Research (23)

More Publications

Publishers
  1. American Society of Clinical Oncology (164)
  2. Elsevier Inc. (118)
  3. Oxford University Press (113)
  4. American Association for Cancer Research (78)
  5. Nature Publishing Group (27)
  6. S. Karger AG (23)

More Publishers

Results (636)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Phase II trial of bortezomib in KRAS G12D mutant lung cancers
    Meeting Abstract

    Litvak, A. M.; Drilon, A. E.; Rekhtman, N.; Pietanza, M. C.; Chaft, J. E.; Woo, K.; Paik, P. K.; Kris, M. G.; Riely, G. J.
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • A phase 1, open-label, dose-escalation study of SNX-5422 plus carboplatin and paclitaxel in subjects with advanced lung cancers
    Meeting Abstract

    Gutierrez, M.; Giaccone, G.; Harper, H. D.; Liu, S. V.; Fang, B.; Ruiz, J.; Hinson, J. M.; Orlemans, E. O.; Drilon, A. E.
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • Phase I trial of the HSP-90 inhibitor PU-H71
    Meeting Abstract

    Gerecitano, J. F.; Modi, S.; Rampal, R.; Drilon, A. E.; Fury, M. G.; Gounder, M. M.; Harding, J. J.; Hyman, D. M.; Varghese, A. M.; Voss, M. H.; more...
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • Physician toxicity attribution in phase I trials: Evaluating the effect of dose on the frequency of 11,909 toxicities
    Meeting Abstract

    Eaton, A.; Iasonos, A.; Gounder, M. M.; Pamer, E.; Drilon, A. E.; Vulih, D.; Smith, G. L.; Ivy, P.; Spriggs, D. R.; Hyman, D. M.
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • Phase II study of cabozantinib for patients with advanced RET-rearranged lung cancers
    Meeting Abstract

    Drilon, A. E.; Sima, C. S.; Somwar, R.; Smith, R.; Ginsberg, M. S.; Riely, G. J.; Rudin, C. M.; Ladanyi, M.; Kris, M. G.; Rizvi, N. A.
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • Dermatologic toxicities of 3,517 solid tumor patients on phase I clinical trials of the National Institutes of Health Cancer Therapy Evaluation Program (CTEP)
    Meeting Abstract

    Drilon, A. E.; Eaton, A.; Schindler, K.; Gounder, M. M.; Smith, G. L.; Vulih, D.; Harris, P. J.; Spriggs, D. R.; Ivy, P.; Iasonos, A.; more...
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • Comprehensive assessment of targetable alterations in lung adenocarcinoma samples with limited material using MSK-IMPACT, a clinical, hybrid capture-based, next-generation sequencing (NGS) assay
    Meeting Abstract

    Arcila, M. E.; Yu, H. A.; Drilon, A. E.; Riely, G. J.; Zehir, A.; Sadowska, J.; Hyman, D. M.; Kris, M. G.; Berger, M. F.; Ladanyi, M.
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • Response to MET inhibitors in patients with stage IV lung adenocarcinomas harboring met mutations causing exon 14 skipping
    Journal Article

    Paik, P. K.; Drilon, A.; Fan, P. D.; Yu, H.; Rekhtman, N.; Ginsberg, M. S.; Borsu, L.; Schultz, N.; Berger, M. F.; Rudin, C. M.; more...
    Cancer Discovery (2015)

    Fulltext@MSK | Save
  • MAP2K1 (MEK1) mutations define a distinct subset of lung adenocarcinoma associated with smoking
    Journal Article

    Arcila, M. E.; Drilon, A.; Sylvester, B. E.; Lovly, C. M.; Borsu, L.; Reva, B.; Kris, M. G.; Solit, D. B.; Ladanyi, M.
    Clinical Cancer Research (2015)

    Fulltext@MSK | Save
  • Comprehensive assessment of targetable driver alterations in lung adenocarcinomas using a clinical, hybrid capture-based, next-generation sequencing assay
    Meeting Abstract

    Arcila, M.; Zehir, A.; Cheng, D.; Yu, H.; Kris, M.; Drilon, A.; Riely, G.; Berger, M.; Ladanyi, M.
    Modern Pathology (2015)

    Fulltext@MSK | Save